Respirology Case Reports · 2020 · 11 citations · 6 references
MedicineOncologyPathologyChemotherapyMedical OncologyThoracic OncologyAntifungal AgentsAntifungal TherapyFungal InfectionsLung CancerPulmonary InfectionsPulmonary PathologyAspergillosis TherapyCavitary Lung InfectionFungal Lung DiseaseImmune Checkpoint Inhibitor TherapyLung Squamous Cell CarcinomaPulmonary AspergillosisPulmonary Fungal InfectionsSquamous Cell Carcinoma Pathology
Abstract A 68‐year‐old male patient with squamous cell carcinoma (cT4N2M0) of the left upper lobe received chemoradiotherapy followed by durvalumab, an immune checkpoint inhibitor. The tumour responded well to the therapy, but an infiltrative shadow appeared in the left upper lobe, which was outside the radiation field. Despite treatment with corticosteroid and antibiotics, the development of a cavitary lesion was noted. As Aspergillus fumigatus was isolated from the bronchoscopy specimen, antifungal agents were also administered, but the cavitary lesion further developed. Because his general condition worsened and the entire left lung was destroyed, the patient underwent a left pneumonectomy and recovered without recurrence. The pathology of the removed lung revealed a scarred nodule with granulation tissue around and a cavernous lesion having a necrotic substance inside. We considered that durvalumab might further accelerate the inflammatory response, which had been introduced by fungal infection, leading to uncontrollable inflammation of the lung.
6
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.5K citations · Full text
Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab
Naohiro Uchida, Kohei Fujita, Koichi Nakatani et al. · Respirology Case Reports · 2017 · 49 citations · Full text
Medicine, Immunology, Oncology +17